Robert  Blanks net worth and biography

Robert Blanks Biography and Net Worth

Insider of Ardelyx
Rob has served as our Chief Regulatory Affairs and Quality Assurance Officer since 2020. Before that, Rob had served as our head of regulatory affairs and quality assurance since August 2013. Rob has over 20 years of experience in the pharmaceutical industry in the quality, regulatory and CMC areas. A majority of this experience has been with small biotech companies, where he has played a critical role in developing companies’ initial drug product candidates, including peptides, monoclonal antibodies and small molecules, from the pre-clinical stage to commercial registration.

Prior to Ardelyx, Rob was vice president of CMC at Flexion Therapeutics where he oversaw the manufacture of the company’s initial two drug product candidates, one of which Zillretta™, is in late Phase 3 development. Prior to Flexion, he was vice president of quality at Idenix Pharmaceuticals, overseeing all quality aspects of the commercial launch of the company’s first product, Tyzeka®. Previous to Idenix, he served as vice president of technical operations for Trine Pharmaceuticals and earlier was vice president of technical operations and founder of Phaedrus Pharmaceuticals. At GelTex Pharmaceuticals, subsequently purchased by Genzyme, he was a key participant in both the quality and regulatory areas in the development and registration of RenaGel®.

What is Robert Blanks' net worth?

The estimated net worth of Robert Blanks is at least $2.69 million as of February 20th, 2024. Mr. Blanks owns 368,186 shares of Ardelyx stock worth more than $2,687,758 as of March 28th. This net worth approximation does not reflect any other investments that Mr. Blanks may own. Additionally, Mr. Blanks receives an annual salary of $590,800.00 as Insider at Ardelyx. Learn More about Robert Blanks' net worth.

How old is Robert Blanks?

Mr. Blanks is currently 64 years old. There are 6 older executives and no younger executives at Ardelyx. Learn More on Robert Blanks' age.

What is Robert Blanks' salary?

As the Insider of Ardelyx, Inc., Mr. Blanks earns $590,800.00 per year. There are 6 executives that earn more than Mr. Blanks. The highest earning executive at Ardelyx is Mr. Michael G. Raab, President, CEO & Director, who commands a salary of $1,280,000.00 per year. Learn More on Robert Blanks' salary.

How do I contact Robert Blanks?

The corporate mailing address for Mr. Blanks and other Ardelyx executives is 34175 ARDENWOOD BOULEVARD SUITE 200, FREMONT CA, 94555. Ardelyx can also be reached via phone at (510) 745-1700 and via email at [email protected]. Learn More on Robert Blanks' contact information.

Has Robert Blanks been buying or selling shares of Ardelyx?

During the past quarter, Robert Blanks has sold $43,898.75 in shares of Ardelyx stock. Most recently, Robert Blanks sold 5,017 shares of the business's stock in a transaction on Tuesday, February 20th. The shares were sold at an average price of $8.75, for a transaction totalling $43,898.75. Following the completion of the sale, the insider now directly owns 368,186 shares of the company's stock, valued at $3,221,627.50. Learn More on Robert Blanks' trading history.

Who are Ardelyx's active insiders?

Ardelyx's insider roster includes Robert Blanks (Insider), Elizabeth Grammer (Insider), Jeffrey Jacobs (Insider), Michael Raab (CEO), David Rosenbaum (Insider), and Scott Sandell (Major Shareholder). Learn More on Ardelyx's active insiders.

Are insiders buying or selling shares of Ardelyx?

In the last year, insiders at the biopharmaceutical company sold shares 30 times. They sold a total of 637,490 shares worth more than $3,824,112.43. The most recent insider tranaction occured on March, 20th when insider Elizabeth A Grammer sold 86,000 shares worth more than $664,780.00. Insiders at Ardelyx own 5.5% of the company. Learn More about insider trades at Ardelyx.

Information on this page was last updated on 3/20/2024.

Robert Blanks Insider Trading History at Ardelyx

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
2/20/2024Sell5,017$8.75$43,898.75368,186View SEC Filing Icon  
6/23/2023Sell33,333$3.63$120,998.79266,134View SEC Filing Icon  
10/5/2022Sell100,000$1.50$150,000.00195,827View SEC Filing Icon  
8/26/2022Sell21,842$1.04$22,715.68295,827View SEC Filing Icon  
7/26/2022Sell5,188$0.67$3,475.96319,127View SEC Filing Icon  
2/22/2022Sell1,752$0.67$1,173.84View SEC Filing Icon  
9/1/2020Sell2,049$5.58$11,433.42View SEC Filing Icon  
See Full Table

Robert Blanks Buying and Selling Activity at Ardelyx

This chart shows Robert Blanks's buying and selling at Ardelyx by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Ardelyx Company Overview

Ardelyx logo
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
Read More

Today's Range

Now: $7.30
Low: $7.25
High: $7.59

50 Day Range

MA: $8.74
Low: $7.30
High: $9.74

2 Week Range

Now: $7.30
Low: $3.16
High: $10.13

Volume

6,718,669 shs

Average Volume

6,321,907 shs

Market Capitalization

$1.70 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.88